The Effects of Synthesized Semicarbazone Copper Complex on Blood Pressure in Normotensive and L-NAME Induced Hypertensive Rats
Author(s): Keaton A Logan, Helen Asemota, Chukwuemeka Nwokocha, Mark A Lawrence, Rory Thompson, Magdalene Nwokocha, Mohammed Bakir
Hypertension has been for decades a major contributor to overall mortality and morbidity worldwide. This study was aimed towards evaluating changes in blood pressure in normotensive and L-NAME hypertensive induced rats subjected to treatment with a synthesized semicarbazone copper complex (CSCZ)**. CSCZ was synthesized from the reaction between di-2-pyridylketone semicarbazone (dpksc) and CuCl2.2H2O in refluxing ethanol and characterized from its spectroscopic and elemental analyses. The infrared and electronic absorption spectra are in accord with the proposed formulation of the complex. Animals were rendered hypertensive by oral administrations of Nω-nitro-L-arginine methyl ester (L-NAME) daily (dose 40 mg/kg body weight) for 5 weeks. Oral daily dosages (20 mg/kg body weight) of CSCZ was administered to the animals. A significant decrease in systolic blood pressure (SBP) at 132.91 ± 7.62 was observed in the L-NAME/CSCZ treated group (LCZ) when compared to the L-NAME group at 161.00 ± 5.34 while no significant changes were observed in heart rate (HR) and pulse pressure (PP). Treatment with CSCZ also seemingly normalised and prevented the development of L-NAME induced hypertension in the rats. A significant decrease in SBP and PP was also seen in the normotensive group treated with CSCZ at 91 ± 2.11 and 21.67 ± 1.43 respectively when compared to the control group at 130.63 ± 2.98 and 44.10 ± 5.15 respectively. These findings reveal the blood pressure lowering effects of CSCZ in normotensive rats and its ability to prevent L-NAME induced hypertension.